Locations:
Search IconSearch

Tag: alzheimer’s disease (AD)

20-NEU-1975345 cycling-at-home_650x450
January 19, 2021/Geriatrics

CYCLE-AD Trial: High-Intensity Exercise to Stave Off Alzheimer’s Disease

New NIH-funded study tests home-based intervention in high-risk group

20-NEU-1971409_welcome-to-Nevada_650x450
September 18, 2020/Geriatrics

Getting Serious About Curbing Rural Disparities in Dementia Care and Research

NIA grant helps establish Nevada exploratory Alzheimer’s Disease Research Center

20-NEU-1929108_CQD_650x450_1206728074
August 13, 2020/Geriatrics

New Insights Into Inflammation-Related Pathways Predicting Cognitive Decline in Alzheimer’s

Longitudinal study implicates a specific pathway in mild cognitive impairment stage

20-NEU-1918414-alzheimer-brain-650×450

Studies of an Alpha-1 Adrenergic Agonist for Alzheimer’s Advance With New NIA Grant

$2 million will enable preclinical dose and efficacy testing of “compound 3”

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

20-NEU-1909917 Women’s Alzheimer’s Prevention Center_CQD_650x450_CCC-1901608_06-03-20_0907

Newly Launched Alzheimer’s Center Is First in the Nation Focused Solely on Women

Mission centers on screening, prevention for at-risk women in their 30s to 60s

19-NEU-3860-alzheimer-brain-650×450
July 10, 2019/Geriatrics

Cleveland Alzheimer’s Disease Research Center to Be Created With $4.23 Million NIA Grant

Local population, deep expertise portend a center with high impact

18-NEU-Alzheimers-Brain-650×450

Funding Award Enables First Study to Examine Cognitive Effects of an Alpha-1 Agonist

Cleveland Clinic-developed “compound 3” begins testing in preclinical Alzheimer’s model

18-NEU-5506-Phase-3-Alzheimers-Trials-650×450
August 27, 2018/Geriatrics

Analysis of Alzheimer’s Drug Pipeline Reveals Slow Progress, a Few Bright Spots

Third annual report shows shift toward prevention studies, disease-modifying therapies

18-NEU-813-Jeffrey-Cummings-MD-650×450
August 23, 2018/Geriatrics

A Giant of Alzheimer’s Research Surveys the State of His Field

Two career achievement awards prompt Dr. Jeffrey Cummings to look back — and ahead

18-NEU-687 Yan-650×450

Reversal of Alzheimer’s in Mouse Model Boosts BACE1 Inhibitors’ Prospects in Humans

Most substantial reversal of amyloid deposition in an animal study to date

BackPage 3 of 4Next

Advertisement

Ad